Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Can-Fite Biopharma Ltd Sponsored ADR (Israel) (NY:CANF)

1.091 -0.009 (-0.85%)
Streaming Delayed Price Updated: 2:04 PM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Can-Fite Biopharma Ltd Sponsored ADR (Israel)

< Previous 1 2 3 4 5 6 7 Next >
Can-Fite Gears Up to Initiate Pivotal Phase III Liver Cancer Study
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Stock Gains On Piclidenoson Development Pact For Pets
Can-Fite BioPharma Ltd (NYSE: CANF) has signed a development and commercialization agreement with France-based veterinary biotech company, Vetbiolix, to... 
Via Benzinga
Can-Fite Enters Projected $3 Billion Veterinary Osteoarthritis Market: Signs Agreement with Vetbiolix for Development of Piclidenoson for Pets
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Receives Notice of Patent Allowance in China for NASH Treatment
From Can-Fite BioPharma Ltd.
Via Business Wire
CAN-FITE AHEAD OF SCHEDULE IN ITS FIGHT TO TREAT NASH AND LESSEN THE NEED FOR LIVER TRANSPLANTS
Nonalcoholic steatohepatitis (NASH) is the leading cause of disease leading to liver transplants among women and the second-leading cause for liver transplants overall. In... 
Via Benzinga
Can-Fite To Initiate Phase IIb NASH Study with its Drug Candidate Namodenoson
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite to Present at BIO Digital International Convention & Conduct One-on-One Meetings with Potential Partners on June 10-18, 2021
From Can-Fite BioPharma Ltd.
Via Business Wire
CAN-FITE BIOPHARMA ANNOUNCES ADVANCEMENT OF CLINICAL STUDIES AND NEW EUROPEAN LICENSING AGREEMENTS
by Mark Gilman Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI), an Israeli-based biotechnology company advancing a pipeline of proprietary small-molecule drugs that address... 
Via Benzinga
Can-Fite Reports First Quarter 2021 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)... 
Via Benzinga
Exposures COVID-19
Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
From Can-Fite BioPharma Ltd.
Via Business Wire
CAN-FITE BIOPHARMA GAINS ANALYST "BUY" DISTINCTION AND SIGNS NEW DISTRIBUTION AGREEMENTS FOR ITS LEAD DRUG CANDIDATES
Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver... 
Via Benzinga
Can-Fite to Present at Benzinga’s Global Small Cap Conference on May 13, 2021
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite’s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021
From Can-Fite BioPharma Ltd.
Via Business Wire
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:... 
Via Benzinga
Can-Fite Expands Mid-Stage COVID-19 Study To Europe
Can-Fite BioPharma Ltd (NYSE: CANF) has expanded its Phase 2 COVID-19 study of Piclidenoson to two European countries, Romania and Bulgaria. The randomized,... 
Via Benzinga
Exposures COVID-19
Can-Fite Expands its Phase II COVID-19 Study to Europe
From Can-Fite BioPharma Ltd
Via Business Wire
Can-Fite Starts Preclinical Studies Required By FDA, EMA For Two Lead Drug Candidates Registration Filing
Can-Fite BioPharma (NYSE: CANF) has initiated a series of preclinical studies required by regulators to support potential marketing registration filings for... 
Via Benzinga
Exposures Product Safety
Can-Fite Initiates Preclinical Studies Required by FDA and EMA for the Registration of its Two Lead Drug Candidates
From Can-Fite BioPharma Ltd.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.